Venetoclax-Based Salvage Therapy in Patients With Relapsed/Refractory AML Previously Treated With FLT3 or IDH1/2 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
Leukemia and Lymphoma 2022 Oct 26;[EPub Ahead of Print], JP Bewersdorf, RM Shallis, A Derkach, AD Goldberg, A Stein, EM Stein, G Marcucci, AM Zeidan, S Shimony, DJ DeAngelo, RM Stone, I Aldoss, BJ Ball, M StahlFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.